GFAP and Alzheimer disease: After combining with serum SV2A, the AUCs of NfL, GFAP, and p-tau217 for the differential diagnosis between aMCI and AD significantly improved to 73.4%, 76.4%, and 72.7%, respectively (p < 0.01) (Fig. 3i).